

1490–1497). Methods of use claims are directed to treatments preventing the inflammatory response of colitis by modulating IL–13 and NKT cell activity and to methods for screening for therapeutic compounds effective for colitis.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 30, 2007.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E7–8892 Filed 5–8–07; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of Biotechnology Activities; Recombinant DNA Research: Proposed Actions Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)

**ACTION:** Notice of consideration of proposed actions under the NIH Guidelines.

**SUMMARY:** Proposals to conduct research involving the deliberate transfer of a tetracycline resistance trait to *Chlamydia Trachomatis* have been submitted to the NIH Office of Biotechnology Activities (OBA). The acquisition of this antibiotic resistance trait could possibly compromise the use of a class of antibiotics for the treatment of Chlamydia infections in humans. Under the NIH Guidelines, these experiments can proceed only after they are reviewed by the NIH Recombinant DNA Advisory Committee (RAC) and specifically approval by the NIH Director as Major Actions. These

proposals will be discussed at the June 19–21, 2007 meeting of NIH Recombinant DNA Advisory Committee.

**DATES:** The public is encouraged to submit written comments on these proposed actions. Comments may be submitted to the OBA in paper or electronic form at the OBA mailing, fax, and e-mail addresses shown below under the heading **FOR FURTHER INFORMATION**. The NIH will consider all comments submitted by June 15, 2007. Written comments submitted by May 24, 2007 will be reproduced and distributed to the RAC for consideration at its June 19–21 meeting. In addition, an opportunity for public comment will be provided at that meeting. All written comments received in response to this notice will be available for public inspection at the NIH OBA office, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892 (telephone, 301–496–9838), weekdays between the hours of 8:30 a.m. and 5 p.m.

**FOR FURTHER INFORMATION CONTACT:**

Contact OBA by e-mail at [oba@od.nih.gov](mailto:oba@od.nih.gov), or telephone at 301–496–9838, if you have questions, or require additional information about these proposed actions. Comments may be submitted to the same e-mail address or by fax at 301–496–9839 or sent by U.S. mail to the Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, Maryland 20892–7985. For additional information about the RAC meeting at which these proposed actions will be deliberated, please visit the NIH OBA Web site at: <http://www4.od.nih.gov/oba/>.

**SUPPLEMENTARY INFORMATION:** OBA has received information from two Institutional Biosafety Committees regarding proposed experiments, which, to proceed, would require Major Actions under Section III–A–1–a of the NIH Guidelines. Under this section, if the deliberate transfer of a drug resistance trait to microorganisms could compromise the use of the drug to control disease in humans, veterinary medicine, or agriculture the experiment must be reviewed by the RAC. Dr. Dan Rockey and Dr. Walter Stamm (at Oregon State University and the University of Washington, respectively), are proposing to develop a genetic transformation system to study the pathogenesis of *Chlamydia trachomatis*, a human pathogen that is a leading cause of sexually transmitted disease worldwide and, mostly in the developing world, a preventable cause of blindness. Per the investigators, the lack of genetic tools to study the mechanisms of pathogenesis in these

obligate intracellular bacterial parasites hinders research. The recent discovery of naturally occurring tetracycline resistant strains of *C. suis* (a swine pathogen) may provide the necessary genetic elements to develop such a transformation system. To accomplish this goal, experiments are planned to transfer tetracycline resistance from *C. suis* into *C. trachomatis* (a human pathogen). It is asserted that success in these proposed studies will lead to opportunities for “rapid developments in our understanding of chlamydial biology.” The investigators are proposing to perform these experiments under Biosafety Level 2 containment.

Background information may be obtained by contacting NIH OBA via e-mail at [oba@od.nih.gov](mailto:oba@od.nih.gov). Alternatively, information is available on the OBA Web site at <http://www4.od.nih.gov/oba/rac/latestnewsrac.htm>.

Dated: May 3, 2007.

**Amy P. Patterson,**

*Director, Office of Biotechnology Activities, National Institutes of Health.*

[FR Doc. E7–8900 Filed 5–8–07; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[USCG–2007–28034]

#### Chemical Transportation Advisory Committee; Vacancies

**AGENCY:** Coast Guard, DHS.

**ACTION:** Request for applications.

**SUMMARY:** The Coast Guard is seeking applications for appointment to membership on the Chemical Transportation Advisory Committee (CTAC). CTAC advises, consults with, and makes recommendations to the Coast Guard on matters relating to the safe and secure transportation and handling of hazardous materials in bulk on U.S.-flag vessels in U.S. ports and waterways.

**DATES:** Application forms should reach the Coast Guard on or before August 31, 2007.

**ADDRESSES:** You may request an application form by writing to Commandant (CG–3PSO–3), U.S. Coast Guard, 2100 Second Street SW., Washington, DC 20593–0001; by calling (202) 372–1425/1422; or by faxing (202) 372–1926. Submit application forms to the same address. This notice and the application form are available on the Internet at <http://dms.dot.gov>. The application form is also available at

<http://www.uscg.mil/hq/g-m/advisory/ctac/ctac.htm>.

**FOR FURTHER INFORMATION CONTACT:**

Commander Richard J. Raksnis, Executive Director of CTAC, or Ms. Sara S. Ju, Assistant to the Executive Director, telephone (202) 372-1425/1422, fax (202) 372-1926.

**SUPPLEMENTARY INFORMATION:** The Chemical Transportation Advisory Committee (CTAC) is an advisory committee constituted under the Federal Advisory Committee Act, 5 U.S.C. App. 2. It advises, consults with, and makes recommendations to the Commandant through the Assistant Commandant for Prevention on matters relating to the safe and secure transportation and handling of hazardous materials in bulk on U.S.-flag vessels in U.S. ports and waterways. The advice and recommendations of CTAC also assist the U.S. Coast Guard in formulating the position of the United States on hazardous material transportation issues prior to meetings of the International Maritime Organization.

CTAC meets at least once a year, usually twice a year, at Coast Guard Headquarters in Washington, DC, or in another location. CTAC's subcommittees and working groups may meet to perform specific assignments as required.

The Coast Guard will consider applications for eight positions that expire on December 31, 2007. To be eligible, applicants should have experience associated with, and represent the viewpoints of, the following areas associated with marine chemical transportation: Chemical manufacturing, vessel design and construction, safety and security, marine environmental protection, or marine handling or transportation of chemicals. Each member serves for a term of 3 years. Some members may serve consecutive terms. All members serve at their own expense, and receive no salary, reimbursement of travel expenses, or other compensation from the Federal Government. While CTAC Charter expires on July 5, 2007, appointments will be made in anticipation of a renewal of the CTAC Charter.

In support of the policy of the Department of Homeland Security on gender and ethnic diversity, the Coast Guard encourages applications from qualified women and members of minority groups.

Dated: April 26, 2007.

**J.G. Lantz,**

*Director of National and International Standards, Assistant Commandant for Prevention.*

[FR Doc. E7-8856 Filed 5-8-07; 8:45 am]

**BILLING CODE 4910-15-P**

**DEPARTMENT OF HOMELAND SECURITY**

**Transportation Security Administration**

**Extension of Agency Information Collection Activity Under OMB Review: Department of Homeland Security Traveler Redress Inquiry Program (DHS TRIP)**

**AGENCY:** Transportation Security Administration, DHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces that the Transportation Security Administration (TSA) has forwarded the Information Collection Request (ICR) abstracted below to the Office of Management and Budget (OMB) for review and approval of an extension of the currently approved collection under the Paperwork Reduction Act. The ICR describes the nature of the information collection and its expected burden. TSA published a **Federal Register** notice, with a 60-day comment period soliciting comments, of the following collection of information on January 5, 2007, 72 FR 576. The collection involves the submission of identifying and travel experience information by individuals requesting redress through DHS TRIP.

**DATES:** Send your comments by June 8, 2007. A comment to OMB is most effective if OMB receives it within 30 days of publication.

**ADDRESSES:** Interested persons are invited to submit written comments on the proposed information collection to the Office of Information and Regulatory Affairs, Office of Management and Budget. Comments should be addressed to Nathan Lesser, Desk Officer, Department of Homeland Security/TSA, and sent via electronic mail to [oir\\_submission@omb.eop.gov](mailto:oir_submission@omb.eop.gov) or faxed to (202) 395-6974.

**FOR FURTHER INFORMATION CONTACT:**

Joanna Johnson, Program Analyst, Office of Communications, Business Management Office, Operational Process and Technology, TSA-11, Transportation Security Administration, 701 South 12th Street, Arlington, VA 22202-4220; telephone (571) 227-3651; facsimile (571) 227-3885.

**SUPPLEMENTARY INFORMATION:**

**Comments Invited**

In accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*), an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a valid OMB control number. The ICR documentation is available at [www.reginfo.gov](http://www.reginfo.gov). Therefore, in preparation for OMB review and approval of the following information collection, TSA is soliciting comments to—

(1) Evaluate whether the proposed information requirement is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agency's estimate of the burden;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including using appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**Information Collection Requirement**

*Title:* Department of Homeland Security Traveler Redress Inquiry Program (DHS TRIP).

*Type of Request:* Extension of a currently approved collection.

*OMB Control Number:* 1652-0044.

*Form(s):* Traveler Inquiry Form, Third Party Consent Form.

*Affected Public:* Traveling public.

*Abstract:* The Rice-Chertoff Initiative (RCI) Department of Homeland Security Traveler Redress Inquiry Program (DHS TRIP) was developed as a voluntary program by DHS to provide a one-stop mechanism for individuals to request redress who believe they have been: (1) Denied or delayed boarding; (2) denied or delayed entry into or departure from the United States at a port of entry; or (3) identified for additional (secondary) screening at our Nation's transportation hubs, including airports, seaports, train stations and land borders. The DHS TRIP office will be located at, and managed by, TSA. In order for individuals to request redress, they are asked to provide identifying information, as well as details of the travel experience. Individuals can do so online at <http://www.dhs.gov/trip>. DHS TRIP then passes the information to the relevant DHS component to process the request, as appropriate. This collection serves to distinguish individuals from an actual individual on any watch list used by DHS, and it helps streamline